$39.80
-0.15-0.38%
At close: Dec 15, 4:00 PM EST
Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Compare Best Stocks
Comments
Loading...
Virtus LifeSci Biotech Clinical Trials ETF (BBC) Stock Price, Quote, News & History
BBCARCA
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
29.96M
Fund Score
Key Statistics
Open
$40.25
High
$40.65
52 Wk High
$40.82
AUM
29.96M
Dividend
$0.24
Ex-Div Date
Dec 20, 2024
Volume
13.88K
Market Cap
$1.90B
Mgmt Fee
0.79%
P/E Ratio
20.66
Prev. Close
$39.95
Low
$39.79
52 Wk Low
$13.42
Shares Out
400.00K
Yield
0.60%
Div. Freq
-
Avg. Volume Daily
26.88K
Beta
0.92
Avg. Expense Ratio
0.79%
P/B Ratio
2.94
Recent Virtus LifeSci Biotech Clinical Trials ETF News
FAQ
Q
How do I buy Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
You can purchase shares of Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) through any online brokerage.
Q
Who are Virtus LifeSci Biotech Clinical Trials ETF (BBC) competitors?
A
There are no as such competitors for Virtus LifeSci Biotech Clinical Trials ETF.
Q
What is the forecast, or price target, for Virtus LifeSci Biotech Clinical Trials ETF (BBC) stock?
A
There is no analysis for Virtus LifeSci Biotech Clinical Trials ETF to provide a consensus price target.
Q
What is the current price for Virtus LifeSci Biotech Clinical Trials ETF (BBC)?
A
The stock price for Virtus LifeSci Biotech Clinical Trials ETF (ARCA: BBC) is $39.8 last updated December 15, 2025 at 6:30 PM EST.
Q
Does Virtus LifeSci Biotech Clinical Trials ETF (BBC) pay a dividend?
A
There are no upcoming dividends for Virtus LifeSci Biotech Clinical Trials ETF.
Q
When is Virtus LifeSci Biotech Clinical Trials ETF (ARCA:BBC) reporting earnings?
A
Virtus LifeSci Biotech Clinical Trials ETF does not have any upcoming earnings scheduled.
Q
Is Virtus LifeSci Biotech Clinical Trials ETF (BBC) going to split?
A
There is no upcoming split for Virtus LifeSci Biotech Clinical Trials ETF.
Key Statistics
Open
$40.25
High
$40.65
52 Wk High
$40.82
AUM
29.96M
Dividend
$0.24
Ex-Div Date
Dec 20, 2024
Volume
13.88K
Market Cap
$1.90B
Mgmt Fee
0.79%
P/E Ratio
20.66
Prev. Close
$39.95
Low
$39.79
52 Wk Low
$13.42
Shares Out
400.00K
Yield
0.60%
Div. Freq
-
Avg. Volume Daily
26.88K
Beta
0.92
Avg. Expense Ratio
0.79%
P/B Ratio
2.94
About
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 16, 2014 |
| Managers | Matthew B. Brown Seth Kadushin |
| Definition | Most of the stocks in this equity fund have average financial performance and average growth potential |
Investment Policy
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| MLYS | Mineralys Therapeutics... | 1.52% |
| NUVB | Nuvation Bio Inc Pipe | 1.69% |
| CELC | Celcuity Inc Com | 3.61% |
| TERN | Terns Pharmaceuticals ... | 2.84% |
| PRAX | Praxis Precision Medic... | 2.34% |
| GLUE | Monte Rosa Therapeutic... | 1.62% |
| ARWR | Arrowhead Pharmaceutic... | 1.49% |
| MBX | Mbx Biosciences Inc | 1.41% |
| ATXS | Astria Therapeutics In... | 1.36% |
Market Resources
Trading Tools & Education
- Benzinga Pro Trading Platform
- Options Trading Strategies and News
- Stock Market Trading Ideas and Analysis
- Technical Analysis Charts and Indicators
- Fundamental Analysis and Valuation
- Day Trading Guides and Strategies
- Live Investors Events
- Pre market Stock Analysis and News
- Cryptocurrency Market Analysis and News
Ring the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
© 2025 Benzinga | All Rights Reserved